Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Immunoblastic Lymphadenopathy 1

Interventions

Cyclophosphamide 11Doxorubicin 9Vincristine 8Methotrexate 6nelarabine 5Prednisone 5Peripheral Blood Stem Cell Transplantation 5Leucovorin 5Cytarabine 5tanespimycin 4merphos 4fludarabine phosphate 4dexamethasone acetate 4dexamethasone 21-phosphate 4auricularum 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Etoposide 4Dexamethasone 4Cyclosporine 4Calcium Dobesilate 4Bortezomib 4prednylidene 3pegaspargase 3deltacortene 3azathiopurine 3Vorinostat 3Thioguanine 3Radiotherapy 3Pharmacogenomic Testing 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × visilizumab × Clear all
NCT00006009 2013-05-15

Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
DermatologicLymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡